Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1184919-23-0

Post Buying Request

1184919-23-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1184919-23-0 Usage

Uses

Different sources of media describe the Uses of 1184919-23-0 differently. You can refer to the following data:
1. Deschloro-dasatinib, is the impurity of Dasatinib (D193600), which is a new, oral, small-molecule Tyrosine Kinase Inhibitor (TKI) for the treatment of CML. It is also an Antineoplastic.
2. Deschloro-dasatinib, is the impurity of Dasatinib (D193600), which is a new, oral, small-molecule Tyrosine Kinase Inhibitor (TKI) for the treatment of CML. It is also an Antineoplastic. It is a COVID19-related research product.

Check Digit Verification of cas no

The CAS Registry Mumber 1184919-23-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,4,9,1 and 9 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1184919-23:
(9*1)+(8*1)+(7*8)+(6*4)+(5*9)+(4*1)+(3*9)+(2*2)+(1*3)=180
180 % 10 = 0
So 1184919-23-0 is a valid CAS Registry Number.

1184919-23-0Downstream Products

1184919-23-0Relevant articles and documents

INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF

-

Page/Page column 447; 461; 462; 463, (2018/11/22)

The invention is based on the surprising finding that SIK3 is associated with resistance against anti-tumour immune responses. In particular, the invention provides methods for treating proliferative diseases using inhibitors of SIK3, especially nucleic acid or small molecule inhibitors of SIK3. Also provided are methods of sensitising cells involved with a proliferative disorder against the cytotoxic effect of certain pro-inflammatory signalling pathways, and/or to kill such cells and/or methods for treating proliferative diseases, using a SIK3 inhibitor together with ligands or agonists of such signalling pathways. Other methods provided by the invention include those involving SIK3 inhibitors to enhance or overcome certain side effects associated with treatments that utilise such signalling pathways, as well as diagnostic, prognostic and monitoring methods and kits based on the detection of SIK3 in a sample obtained from a subject, and screening methods useful for identifying or characterising inhibitors of SIK3.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1184919-23-0